Notably, mutations in the IFN γ receptor (IFNGR1 and IFNGR2) and downstream signaling molecules, such as STAT1, have been identified as key factors in resistance, as they impair the signaling cascade necessary for IFN-γ-mediated tumor cell death [91]. The gene discussed is IFNG; the disease is neoplasm.